The co-inhibitory receptor TIGIT is also expressed upon T-cell activation to bind CD112, CD113, and CD155 ligands on APC and cancer cells; TIGIT inhibition can improve anti-tumor immune responses in vivo [96]. Here, TIGIT is linked to cancer.